Spina bifida

Lancet

Volumn 364, Issue 9448, 2004, Pages 1885-1895

  Mitchell, Laura E ^a   Scott Adzick, N ^b,c   Melchionne, Jeanne ^b   Pasquariello, Patrick S ^b   Sutton, Leslie N ^b   Whitehead, Alexander S ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AMINOPTERIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYANOCOBALAMIN; FOLIC ACID; FUMONISIN; GLUCOSE; HOMOCYSTEINE; METHOTREXATE; TRANSCRIPTION FACTOR PAX3; TRIMETHOPRIM; VALPROIC ACID;

ANENCEPHALUS; BIPOLAR DISORDER; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; EMBRYOPATHY; EPILEPSY; FAMILY HISTORY; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYPERTHERMIA; MATERNAL DIABETES MELLITUS; MIGRAINE; NEURAL TUBE; PAIN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SPINA BIFIDA; TERATOGENESIS; ULTRASOUND; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 8844265391     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17445-X     Document Type: Conference Paper

References (196)

1. Van Allen MI, Kalousek DK, Chernoff GF, et al. Evidence for multi-site closure of the neural tube in humans. Am J Med Genet. 47:1993;723-743
2. O'Rahilly R, Muller F. The two sites of fusion of the neural folds and the two neuropores in the human embryo. Teratol. 65:2002;162-170
3. Nievelstein RAJ, Hartwig NG, Vermeij-Keers C, Valk J. Embryonic development of the mammalian caudal neural tube. Teratol. 48:1993;21-31
4. O'Rahilly R, Muller F. Summary of the initial development of the human nervous system. Teratol. 60:1999;39-41
5. Copp AJ, Green NDE, Murdoch JN. The genetic basis of mammalian neurulation. Nat Rev Genet. 4:2003;784-793
6. International Clearinghouse for Birth Defects Monitoring Systems. Annual report 1998 with data for 1996. Rome: International Centre for Birth Defects, 1998.
7. Moore CA, Li S, Hong S, et al. Elevated rates of severe neural tube defects in a high-prevalence area in northern China. Am J Med Genet. 73:1997;113-118
8. McDonnell RJ, Johnson Z, Delaney V, Dack P. East Ireland 1980-1994: epidemiology of neural tube defects. J Epidemiol Community Health. 53:1999;782-788
9. Feuchtbaum LB, Currier RJ, Riggle S, Roberson M, Lorey FW, Cunningham GC. Neural tube defect prevalence in California (1990-1994): eliciting patterns by type of defect and maternal race/ethnicity. Genet Test. 3:1999;265-272
10. Chan A, Robertson EF, Haan EA, Keane RJ, Ranieri E, Carney A. Prevalence of neural tube defects in South Australia, 1996-91: effectiveness and impact of prenatal diagnosis. BMJ. 307:1966;703-706
11. Centers for Disease Control. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis - United States, 1985-1994. MMWR Morb Mortal Wkly Rep 1995; 44 (SS-4): 1-13.
12. Velie EM, Shaw GM. Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989-1991. Am J Epidemiol. 144:1995;473-479
13. Mansfield C, Hopfer S, Marteau TM. Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. Prenat Diag. 19:1999;808-812
14. Kallen B, Robert E, Harris J. Associated malformations in infants and fetuses with upper or lower neural tube defects. Teratol. 57:1998;56-63
15. Hall JG, Solehdin F. Genetics of neural tube defects. Ment Retard Dev Disabil Res Rev. 4:1998;269-281
16. Renwick JH. Hypothesis: ancephaly and spina bifida are usually preventable by avoidance of a specific but unidentified substance present in certain potato tubers. Br J Prev Soc Med. 26:1972;67-88
17. Todoroff K, Shaw GM. Prior spontaneous abortion, prior elective termination, interpregnancy interval, and risk of neural tube defects. Am J Epidemiol. 151:2000;505-511
18. Williamson EM. Incidence and familial aggregation of major congenital malformations of the central nervous system. J Med Genet. 2:1965;161-172
19. Carter CO, David PA, Laurence KM. A family study of major congenital malformations of the nervous system in south Wales. J Med Genet. 5:1968;81-106
20. Carter CO, Evans K. Spina bifida and anencephaly in greater London. J Med Genet. 10:1973;209-234
21. Hunter AGW. Neural tube defects in eastern Ontario and western Quebec: demographic and family data. Am J Med Genet. 19:1984;45-63
22. Demenais F, Le Merrer M, Briard ML, Elston RC. Neural tube defects in France: segregation analysis. Am J Med Genet. 11:1982;287-298
23. Janerich DT, Piper J. Shifting genetic patterns in anencephaly and spina bifida. J Med Genet. 15:1978;101-105
24. Zackai EH, Spielman RS, Mellman WJ, et al. The risk of neural tube defects to first cousins of affected individuals. Crandall BF, Brazier MAB. The prevention of neural tube defects: the role of α-fetoprotein. 1978;99-100 Academic Press, New York
25. Barkai G, Arbuzova SBM, Heifetz S, Cuckle H. Frequency of Down's syndrome and neural-tube defects in the same family. Lancet. 361:2003;1331-1335
26. Amorim MR, Castilla EE, Orioli IM. Is there a familial link between Down's syndrome and neural tube defects? Population and familial survey. BMJ. 328:2004;84
27. Wald N. Folic acid and the prevention of neural tube defects. Ann NY Acad Sci. 678:1993;112-128
28. Moore LL, Bradlee ML, Singer MR, Rothman KJ, Milunsky A. Folate intake and the risk of neural tube defects: an estimation of dose-response. Epidemiology. 14:2003;200-205
29. Daly LE, Kirke PN, Molloy AM, Weir DG, Scott JM. Folate levels and neural tube defects. JAMA. 21:1995;1698-1702
30. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet. 358:2001;2069-2073
31. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effects of folic acid. Proc Natl Acad Sci. 93:1996;15227-15232
32. Schorah CJ, Smithells RW. Maternal vitamin nutrition and malformations of the neural tube. Nutr Res Rev. 4:1991;33-49
33. Suarez L, Hendricks K, Felkner M, Gunter E. Maternal serum vitamin B12 levels and risk for neural tube defects in a Texas-Mexico border population. Epidemiology. 13:2003;81-88
34. Ray JG, Blom HJ. Vitamin B12 insufficiency and the risk of fetal neural tube defects. QJM. 96:2003;289-295
35. McLeod L, Ray JG. Prevention and detection of diabetic embryopathy. Community Genet. 5:2002;33-39
36. Greene MF. Diabetic embryopathy 2001: moving beyond the "diabetic milieu" Teratology. 63:2001;116-118
37. Fine E, Horal M, Chang TI, Fortin G, Loeken MR. Evidence that elevated glucose causes altered gene expression, apoptosis, and neural tube defects in a mouse model of diabetic embryopathy. Diabetes. 48:1999;2454-2462
38. Hiramatsu Y, Sekiguchi N, Hayashi M, et al. Diacylglycerol production and protein kinase C activity are increased in a mouse model of diabetic embryopathy. Diabetes. 51:2002;2804-2810
39. Janssen PA, Rothman I, Schwartz SM. Congenital malformations in newborns of women with established and gestational diabetes in Washington state, 1984-91. Paediatr Perinat Epidemiol. 10:1996;52-63
40. Aberg A, Westbom L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev. 61:2001;85-95
41. Sheffield JS, Butler-Koster EL, Casey BM, McIntire DD, Leveno KJ. Maternal diabetes and infant malformations. Obstet Gynecol. 100:2002;925-930
42. Lammer EJ, Sever LE, Oakley GP. Teratogen update: valproic acid. Teratology. 35:1987;465-473
43. Hernandez-Diaz S, Werler MM, Walker AH, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiology. 153:2001;961-968
44. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 16:2002;9-17
45. Koren G. Safe use of valproic acid during pregnancy. Can Fam Physician. 45:1999;1451-1453
46. Pippenger CE. Pharmacology of neural tube defects. Epilepsia. 44:(suppl 3):2003;24-32
47. Hernandez-Diaz S, Werler MM, Walker AH, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 343:2000;1608-1614
48. Nambisan M, Wyszynski DF, Holmes LB. No evidence of a protective effect due to periconceptional folic acid (PCFA) intake on risk for congenital anomalies in the offspring of mothers exposed to antiepileptic drugs (AEDs). Birth Defects Research (Part A) 2003; 67: Abs P45.
49. Little J, Elwood JM. Epidemiology of neural tube defects. Kiely M. Reproductive and Perinatal Epidemiology. 1991;251-336 CRC Press, Boca Raton
50. Waller DK, Mills JL, Simpson JL, et al. Are obese women at higher risk for producing malformed offspring? Am J Obstet Gynecol. 179:1994;541-548
51. Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. JAMA. 275:1996;1093-1096
52. Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology. 7:1996;507-512
53. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA. 275:1996;1089-1092
54. Shaw GM, Todoroff K, Schaffer DM, Selvin S. Maternal height and prepregnancy body mass index as risk factors for selected congenital anomalies. Paediatr Perinat Epidemiol. 14:2000;234-239
55. Hendricks K, Nuno OM, Suarez L, Larsen R. Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans. Epidemiology. 12:2001;630-635
56. Watkins ML, Ratashak SA, Honein MA, Botto LD, Moore CA. Maternal obesity and risk for birth defects. Pediatrics. 111:2003;1152-1158
57. Haddow JE, Mitchell LE, Kloza EM, Thanhauser D. Neural tube defects after gastric bypass. Lancet. 1:1986;1330
58. Martin L, Chavez GF, Adams MJ, et al. Gastric bypass surgery as maternal risk factor for neural tube defects. Lancet. 1:1988;640-641
59. Knudsen LB, Kallen B. Gastric bypass, pregnancy and neural tube defects. Lancet. 2:1986;227
60. Milunsky A, Ulcickas M, Rothman KJ, Willet W, Jick SS, Jick H. Maternal heat exposure and neural tube defects. JAMA. 268:1992;882-885
61. Lynberg MC, Khoury MJ, Lu X, Cocian T. Maternal flu, fever and risk of neural tube defects: a population-based case-control study. Am J Epidemiology. 140:1994;244-255
62. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Maternal fever and birth outcome: a prospective study. Teratol. 58:1998;251-257
63. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever, and medication use as risk factors for neural tube defects. Teratol. 57:1998;1-7
64. Lapunzina P. Ultraviolet light-related neural tube defects? Am J Med Genet. 67:1996;106
65. Shiota K. Neural tube defects and maternal hyperthermia in early pregnancy: epidemiology in a human embryo population. Am J Med Genet. 12:1982;281-288
66. Hendricks K. Fumonisins and neural tube defects in south Texas. Epidemiology. 10:1999;198-200
67. Sadler TW, Merrill AH, Stevens VL, Sullards MC, Wang E, Wang P. Prevention of fumonisin B1-induced neural tube defects by folic acid. Teratol. 66:2002;169-176
68. Felkner M, Hendricks K, Suarez L, Waller DK. Diarrhea: a new risk factor for neural tube defects? Birth Defects Res Part A Clin Mol Teratology. 67:2003;504-508
69. Institute of Medicine. Veterans and agent orange: health effects of herbicide used in Vietnam. 1994;National Academy Press, Washington
70. Institute of Medicine. Veterans and agent orange: update. 1998;1999 National Academy Press, Washington
71. Institute of Medicine. Veterans and agent orange: update. 2000;2001 National Academy of Sciences, Washington
72. Erickson JD, Mulinare J, McClain PW, et al. Vietnam veterans' risks for fathering babies with birth defects. JAMA. 252:1984;903-912
73. Centers for Disease Control. Health status of Vietnam veterans. III. Reproductive outcomes and child health. The Centers for Disease Control Vietnam Experience Study. JAMA. 259:1998;2715-2719
74. Wolfe WH, Michalek JE, Miner JC, et al. Paternal serum dioxin and reproductive outcomes among veterans of Operation Ranch Hand. Epidemiology. 6:1995;17-22
75. Klotz JB, Pyrch LA. Neural tube defects and drinking water disinfection by-products. Epidemiology. 10:1999;383-390
76. Dodds L, King WD. Relation between trihalomethane compounds and birth defects. Occup Environ Med. 58:2001;443-446
77. Blaasaas KG, Tynes T, Lie RT. Risk of birth defects by parental occupational exposure to 50 Hz electromagnetic fields: a population based study. Occup Environ Med. 59:2002;92-97
78. Orr M, Bove F, Kaye W, Stone M. Elevated birth defects in racial or ethnic minority children of women living near hazardous waste sites. Int J Hyg Environ Health. 205:2002;19-27
79. Dolk H, Vrijheid M, Armstrong B, et al. Risk of congenital anomalies near hazardous-waste landfill sites in Europe: the EUROHAZCON study. Lancet. 352:1998;423-427
80. Shaw GM, Wasserman CR, O'Malley CD, Nelson V, Jackson RJ. Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology. 10:1999;60-66
81. Volcik KA, Zhu H, Shaw GM, Lammer EJ, Finnell RF. Apolipoprotein E and apolipoprotein B genotypes and risk for spina bifida. Teratol. 66:2002;257-259
82. Shaw GM, Barber R, Todoroff K, Lammer EJ, Finnell RF. Microsatellites proximal to leptin and leptin receptor as risk factors for spina bifida. Teratol. 61:2000;231-235
83. Volcik KA, Shaw GM, Zhu H, Lammer EJ, Finnell RH. Risk factors for neural tube defects: assocations between uncoupling protein 2 polymorphisms and spina bifida. Birth Defects Res Part A Clin Mol Teratology. 67:2003;924-928
84. Morrison K, Papapetrou C, Hol FA, et al. Susceptibility to spina bifida; an association study of five candidate genes. Ann Hum Genet. 62:1998;379-396
85. Klootwijk R, Hol FA, Wu M, et al. Genetic variation analysis of MLP, TFAP2A, and CSK in patients with neural tube defects. J Med Genet. 40:2003;e43
86. Stumpo DJ, Eddy RL, Haley LL, et al. Promoter sequence, expression, and fine chromosomal mapping of the human gene (MLP) encoding the MARCKS-like protein: identification of neighboring and linked polymorphic loci for MLP and MACS and use in the evaluation of human neural tube defects. Genomics. 49:1998;253-264
87. Stegmann K, Boecker J, Richter B, et al. A screen for mutations in human homologues of mice exencephaly genes Tfap2a and Msx2 in patients with neural tube defects. Teratol. 63:2001;167-175
88. Rogner UC, Danoy P, Matsuda F, Moore GE, Stanier P, Avner P. SNPs in the CpG island of NAP1L2: A possible link between DNA methylation and neural tube defects? Am J Med Genet. 110:2002;208-214
89. Joosten PHLJ, Toepoel M, Mariman ECM, Van Zoelen EJJ. Promoter haplotype combinations of the platelet-derived growth factor alpha-receptor gene predispose to human neural tube defects. Nat Genet. 27:2001;215-217
90. Carrel T, Herman GE, Moore GE, Stanier P. Lack of mutations in ZIC3 in three families with neural tube defects. Am J Med Genet. 98:2001;283-285
91. Felder B, Stegmann K, Schultealbert A, et al. Evaluation of BMP4 and its specific inhibitor NOG as candidates in human neural tube defects (NTDs). Eur J Hum Genet. 10:2002;753-756
92. Volcik KA, Blanton SH, Kruzel MC, et al. Testing for genetic assocations in a spina bifida population: analysis of HOX gene family and human candidate gene regions implicated by mouse models of neural tube defects. Am J Med Genet. 110:2002;203-207
93. Bauer KA, George TM, Enterline DS, et al. A novel mutation in the gene encoding Noggin is not causative in human neural tube defects. J Neurogenet. 16:2002;65-71
94. Stegmann K, Boecker J, Kosan C, Ermert A. Kunz J, Koch MC. Human transcription factor SLUG: mutation analysis in patients with neural tube defects and identification of a missense mutation (D119E) in the SLUG subfamily-defining region. Mutat Res. 406:1999;63-69
95. Zhu H, Barber R, Shaw GM, Lammer EJ, Finnell RF. Is sonic hedgehog (SHH) a candidate gene for spina bifida? A pilot study. Am J Med Genet. 117A:2003;87-88
96. Brown LY, Hodge SE, Johnson WG, Guy SG, Nye JS. Possible association with NTDs with a polyhistidine tract polymorphism in the ZIC2 gene. Am J Med Genet. 108:2002;128-131
97. Finnell RH, Gould A, Spiegelstein O. Pathobiology and genetics of neural tube defects. Epilepsia. 44:(suppl 3):2003;14-23
98. Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects. QJM. 88:1995;763-766
99. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated 5,10-methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 346:1995;1070-1071
100. Botto LD, Yang Q. 5,10-methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 151:2000;862-877
101. Doolin M-T, Barbaux SMM, Hoess K, Whitehead AS, Mitchell LE. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet. 71:2002;1222-1226
102. Brody LC, Conley M, Cox C, et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/ methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the birth defects research group. Am J Hum Genet. 71:2002;1207-1215
103. Wilson A, Platt R, Wu Q, et al. A common variant of methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab. 67:1999;317-323
104. Zhu H, Wicker NJ, Shaw GM, et al. Homocysteine remethylation enzyme polymorphisms and increased risk for neural tube defects. Mol Genet Metab. 78:2003;216-221
105. De Marco P, Calevo MG, Moroni A, et al. Reduced folate carrier polymorphism (80A-G) and neural tube defects. Eur J Hum Genet. 11:2003;245-252
106. van der Put NMJ, Gabreels F, Stevens EMB, et al. A second common mutation in the mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects. Am J Hum Genet. 62:1998;1044-1051
107. Volcik KA, Shaw GM, Lammer EJ, Zhu H, Finnell RF. Evaluation of infant mehylenetetrahydrofolate reductase genotype, maternal vitamin use, and risk of high versus low level spina bifida. Birth Defects Res Part A Clin Mol Teratol. 67:2003;154-157
108. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RF. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet. 108:2002;1-6
109. Shields DC, Kirke PN, Mills JL, et al. The "thermolabile" variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet. 64:1999;1045-1055
110. Posey DL, Khoury MJ, Mulinare J, Adams MJ, Ou CY. Is mutated MTHFR a risk factor for neural tube defects. Lancet. 347:1996;686-687
111. Harris MJ. Why are the genes that cause risk of human neural tube defects so hard to find? Teratology. 63:2001;165-166
112. Wilson V, Rashbass P, Beddington RSP. Chimeric analysis of T (Brachyury) gene function. Development. 117:1993;1321-1331
113. Morrison K, Papapetrou C, Attwood J, et al. Genetic mapping of the human homologue (T) of the mouse T (Brachyury) and a search for allele association between human T and spina bifida. Hum Mol Genet. 5:1996;669-674
114. Trembath D, Sherbondy AL, VanDyke DC, et al. Analysis of select folate pathway genes, PAX3, and human T in a midwestern neural tube defect population. Teratol. 59:1999;331-341
115. Speer MC, Melvin EC, Viles KD, et al. T locus shows no evidence for linkage disequilibrium or mutation in American caucasian neural tube defect families. Am J Med Genet. 110:2002;215-218
116. Shields DC, Ramsbottom D, Donoghue C, et al. Association between historically high frequencies of neural tube defects and the human T homologue of mouse T (Brachyury). Am J Med Genet. 92:2000;206-211
117. Chatkupt S, Hol FA, Shugart YY, et al. Absence of linkage between familial neural tube defects and PAX3 gene. J Med Genet. 32:1995;200-204
118. Hol FA, Geurds MPA, Shugart YY, et al. PAX genes and human neural tube defects: an amino acid substitution in PAX1 in a patient with spina bifida. J Med Genet. 33:1996;655-660
119. Volcik KA, Blanton SH, Kruzel MC, et al. Testing for genetic associations with the PAX gene family in a spina bifida population. Am J Med Genet. 110:2002;195-202
120. Shin J-H, Shiota K. Folic acid supplementation of pregnant mice suppresses heat-induced neural tube defects in the offspring. J Nutr. 129:1999;2070-2073
121. Fleming A, Copp AJ. Embryonic folate metabolism and mouse neural tube defects. Science. 280:1998;2107-2109
122. Zhao Q, Behringer RR, de Crombrugghe B. Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Nat Genet. 13:1996;275-283
123. Carter M, Ulrich S, Oofuji Y, Williams DA, Ross ME. Crooked tail (Cd) models human folate-responsive neural tube defects. Hum Mol Genet. 8:1999;2199-2204
124. Martinez-Barbera JPM, Rodriguez TA, Greene NDE, et al. Folic acid prevents exencephaly in Cited2 deficient mice. Hum Mol Genet. 11:2002;283-293
125. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 4:2002;45-61
126. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 33:2003;177-182
127. Drugan A, Weissman A, Evans MI. Screening for neural tube defects. Clin Perinatol. 28:2001;279-287
128. Loft AG. Determination of amniotic fluid acetylcholinesterase activity in the antenatal diagnosis of foetal malformations: the first ten years. J Clin Chem Clin Biochem. 28:1990;893-911
129. Lennon CA, Gray DL. Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. Obstet Gynecol. 94:1999;562-566
130. Sepulveda W, Corral E, Ayala C, Be C, Gutierrez J, Vasquez P. Chromosomal abnormalities in fetuses with open neural tube defects: prenatal identification with ultrasound. Ultrasound Obstet Gynecol. 23:2004;352-356
131. Mangels K, Tulipan N, Tsao L, Alarcon J, Bruner J. Fetal MRI in the evaluation of intrauterine myelomeningocele. Pediatr Neurosurg. 32:2000;124-131
132. Cochrane DD, Wilson RD, Steinbok P, et al. Prenatal spinal evaluation and functional outcome of patients born with myelomeningocele: information for improved prenatal counseling and outcome prediction. Fetal Diagn Ther. 11:1996;159-168
133. Biggio JR, Owen J, Wenstrom KD, Oakes WJ. Can prenatal ultrasound findings predict ambulatory status in fetuses with open spina bifida? Am J Obstet Gynecol. 185:2001;1016-1020
134. Anteby EY, Yagel S. Route of delivery of fetuses with structural anomalies. Eur J Obstet Gynecol Reprod Biol. 106:2003;5-9
135. Charney EB, Weller SC, Sutton LN, Bruce DA, Schut LB. Management of the newborn with myelomeningocele: time for a decision-making process. Pediatrics. 75:1985;58-64
136. Korenromp M, Good J, Bruinese H, Kriek R. Early fetal movements in myelomeningocele. Lancet. 1:1986;917-918
137. Correia-Pinto J, Reis JL, Hutchins GM, et al. In utero meconium exposure increases spinal cord necrosis in a rat model of myelomeningocele. J Pediatr Surg. 37:2002;488-492
138. Drewek M, Brunner J, Whetsell NT. Quantitative analysis of the toxicity of human amniotic fluid to cultured rate spinal cord. Pediatr Neurosurg. 27:1996;190-193
139. Hutchins G, Meuli M, Meuli-Simmen C, Jordan M, Heffez D, Blakemore K. Acquired spinal cord injury in human fetuses with myelomeningocele. Pediatr Pathol Lab Med. 16:1996;701-712
140. Meuli M, Meuli-Simmen C, Hwang SH, et al. In utero surgery rescues neurological function at birth in sheep with spina bifida. Nat Med. 1:1995;342-347
141. Michejda M, Bacher J. Functional and anatomic recovery in the monkey brain following excision of fetal encephalocele. Pediatr Neurosci. 12:1985;90-95
142. Osaka K, Tanimura T, Matsumoto S. Myelomeningocele before birth. Neurosurgery. 49:1978;711-724
143. Paek BW, Farmer DL, Wilkinson CC, et al. Hindbrain herniation develops in surgically created myelomeningocele but is absent after repair in fetal lambs. Am J Public Health. 183:2000;1119-1123
144. Bruner J, Richards W, Tulipan N, Arney T. Endoscopic coverage of fetal myelomeningocele in utero. Am J Obstet Gynecol. 180:1999;153-158
145. Adzick N, Sutton L, Crombleholme T, Flake A. Successful fetal surgery for spina bifdia. Lancet. 352:1998;1675-1676
146. Tulipan N, Bruner J. Myelomeningocele repair in utero: a report of three cases. Pediatr Neurosurg. 28:1998;177-180
147. Sutton L, Adzick N, Bilaniuk L, Johnson M, Crombleholme T, Flake A. Improvement in hindbrain herniation demonstrated by serial fetal magnetic imaging following fetal surgery for myelomeningocele. JAMA. 282:1999;1826-1913
148. Tulipan N, Hernanz-Schulman M, Lowe LH, Bruner JP. Intrauterine myelomeningocele repair reverses hindbrain herniation. Pediatr Neurosurg. 31:1999;137-142
149. Bruner JP, Tulipan N, Paschall RL, et al. Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus. JAMA. 282:1999;1819-1825
150. Lyerly AD, Gates EA, Cefalo RC, Sugarman J. Toward the ethical evaluation and use of maternal-fetal surgery. Obstet Gynecol. 98:2001;689-697
151. Howe EG. Ethical issues in fetal surgery. Semin Perinatol. 27:2003;446-457
152. MacKenzie TC, Adzick NS. Advances in fetal surgery. J Intensive Care Med. 16:2001;251-262
153. Cortes RA, Farmer DL. Recent advances in fetal surgery. Semin Perinatol. 28:2004;199-211
154. Holmes N, Nguyen H, Farmer D, Baskin L. Fetal intervention for myelomeningocele: effect on postnatal bladder function. J Urol. 166:2001;2383-2386
155. Tulipan N, Bruner JP, Hernanz-Schulman M, Lowe LHWWF, Nickolaus D, Oakes WJ. The effect of intrauterine myelomeningocele repair on the central nervous system structure and neurologic function. Pediatr Neurosurg. 31:1999;183-188
156. Tubbs RS, Chambers MR, Smyth MD, et al. Late gestation intrauterine myelomeningocele repair does not improve lower extremity function. Pediatr Neurosurg. 38:2003;128-132
157. Johnson MP, Sutton LN, Rintoul N, et al. Fetal myelomeningocele repair: short-term clinical outcomes. Obstetrics. 189:2003;482-487
158. Bruner JP, Tulipan N, Reed G, et al. Intrauterine repair of spina bifida: preoperative predictors of shunt-dependent hydrocephalus. Am J Obstet Gynecol. 190:2004;1305-1312
159. Wong LC, Paulozzi LJ. Survival of infants with spina bifida: a population study, 1979-1994. Paediatr Perinat Epidemiol. 15:2001;374-378
160. Hunt GM. Non-selective intervention in newborn babies with open spina bifida: the outcome 30 years on for the complete cohort. Eur J Pediatr Surg 1999; 9 (suppl I): 5-8.
161. Singhal B, Mathew KM. Factors affecting mortality and morbidity in adult spina bifida. Eur J Pediatr Surg 1999; 9(suppl I): 31-32.
162. McDonnell GV, McCann JP. Why do adults with spina bifida and hydrocephalus die? A clinic-based study. Eur J Pediatr Surg 2000; 10 (suppl I): 31-32.
163. Bowman RM, McLone DG, Grant JA, Tomita T, Jacobsen JS. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 34:2001;114-120
164. Rintoul NE, Sutton LN, Hubbard AM, et al. A new look at myelomeningceles: functional level, vertebral level, shunting and the implications for fetal intervention. Pediatrics. 109:2002;409-413
165. Just M, Schwarz M, Ludwig B, Ermert J, Thelen M. Cerebral and spinal MR-findings in patients with post repair myelomeningocele. Pediatr Radiol. 20:1990;262-266
166. Northrup H, Volcik KA. Spina bifida and other neural tube defects. Curr Probl Pediatr. 30:2000;313-332
167. Vachha B, Adams R. Language differences in young children with myelomeningocele and shunted hydrocephalus. Pediatr Neurosurg. 39:2003;184-189
168. Bolt J, Rawicki B, Donellan S. Urological management of spina bifida. Aust Fam Physician 2001; 30 (suppl 2): 21-24.
169. Bauer SB. The management of the myelodysplastic child: a paradigm shift. Br J Urol 2003; 92 (suppl 1): 23-28.
170. Leibold S, Ekmark E, Adams RC. Decision making for a successful bowel continence program. Eur J Pediatr Surg. 10:2000;26-30
171. Perez M, Lemelle JL, Barthelme H, Marquand D, Schmitt M. Bowel management with antegrade colonic enema using a malone or monti conduit - clinical results. Eur J Pediatr Surg. 11:2001;315-318
172. American Academy of Pediatrics Committee on Children with Disabilities. The role of the pediatrician in transitioning children and adolescents with developmental disabilities and chronic illness from school to work and college. Pediatrics. 106:2000;854-856
173. Medical Research Council. Prevention of neural tube defects. Lancet. 338:1991;131-137
174. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. N Engl J Med. 341:1999;1485-1490
175. Kalter H. Folic acid and human malformations: a summary and evaluation. Reprod Toxicol. 14:2000;463-476
176. Turner LA, Morrison H, Prabhakaran VM. Do we need another randomized controlled trial of folic acid alone? Epidemiology. 12:2001;262-265
177. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects (Cochrane Review). Cochrane Database Syst Rev. 3:2001;CD001056
178. Moore LL. Is the jury still out on folic acid and congenital anomalies? Epidemiology. 12:2001;141-144
179. Cornel MC, Erickson JD. Comparison of national policies on periconceptional use of folic acid to prevent spina bifida and anencephaly (SBA). Teratol. 55:1997;134-137
180. Rosano A, Smithells D, Cacciani L, et al. Time trends in neural tube defects prevalence in relation to preventive strategies: an international study. J Epidemiol Community Health. 53:1999;630-635
181. de Walle HEK, de Jong-van den Berg LTW, Cornel MC. Periconceptional folic acid intake in northern Netherlands. Lancet. 353:1999;1187
182. Neimanis IM, Paterson JM, Bain E. Prevention neural tube defects. Survey of preconceptional use of folic acid. Can Fam Physician. 45:1999;1717-1722
183. Petrini JR, Damus K, Johnston RB, Mattison DR. Knowledge and use of folic acid by women of childbearing age-United States, 1995-1998. MMWR Morb Mortal Wkly Rep. 48:1999;325-327
184. Ringel S, Lahat E, Elizov T, et al. Awareness of folic acid for neural tube defect prevention among Israeli women. Teratol. 60:1999;29-32
185. Watson M, Watson L, Bell R, Halliday J. The increasing knowledge of the role of periconceptional folate in Victorian women of childbearing age: follow-up of a randomized community intervention trial. Aust N Z J Public Health. 25:2001;389-395
186. Braekke K, Staff AC. Periconceptional use of folic acid supplements in Oslo. Acta Obstet Gynecol Scand. 82:2003;620-627
187. Food Standards Agency, UK. Board reaches conclusion of folic acid. 2002. www.food.gov.uk/news/newsarchive/2002/may/62488 (accessed Nov 8, 2004).
188. de Walle HEK, Cornel MC, de Jong-van den Berg LTW. Three years after the Dutch folic acid campaign: growing socioeconomic differences. Prev Med 2002; 35: 65-69.
189. Centers for Disease Control. Folate status in women of childbearing age - United States, 1999. Morb Mortal Wkly Rep. 49:2000;962-965
190. Hertrampf E, Cortes F, Erickson JD, et al. Consumption of folic acid-fortified bread improves folate status in women of reproductive age in Chile. J Nutr. 133:2003;3166-3169
191. Mersereau P, Kikler K, Carter H, et al. Spina bifida and anencephaly before and after folic acid mandate - United States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep. 53:2004;362-365
192. Castilla EE, Orioli IM, Lopez-Camelo JS, da Graca Dutra M, Nazer-Herrera J. Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am J Med Genet. 123A:2003;123-128
193. Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE. Association of neural tube defects and folic acid food fortification in Canada. Lancet. 360:2002;2047-2048
194. De Wals P, Rusen ID, Lee NS, Morin P, Niyonsenga T. Trend in prevalence of neural tube defects in Quebec. Birth Defects Res Part A Clin Mol Teratol. 67:2003;919-923
195. Persad VL, Van den Hof MC, Dube JM, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ. 167:2002;241-245
196. Finnell RH, Shaw GM, Lammer EJ, Volcik KA. Does prenatal screening for 5,10-methylenetetrahydrofolate reductase (MTHFR) mutations in high-risk neural tube defect pregnancies make sense? Genet Test. 6:2002;47-52